Johnson & Johnson (JNJ) Return on Invested Capital (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Return on Invested Capital came in at 0.0% in Q1 2026, little changed year-on-year from 0.0% in Q1 2025, and down 3.02% quarter-over-quarter from 0.0% in Q4 2025.
Johnson & Johnson (JNJ) Return on Invested Capital (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Return on Invested Capital across 18 years of filings, most recently posting 0.0% for Q1 2026.
- Return on Invested Capital for Q1 2026 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
- Return on Invested Capital came in at 0.0% for Q1 2026 at Johnson & Johnson, down from 0.0% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 0.0% in Q3 2024 to a low of 0.0% in Q1 2025.
- The 5-year median for Return on Invested Capital is 0.0% (2022), against an average of 0.0%.
- Peak annual rise in Return on Invested Capital reached 0 bps in 2022, while the deepest fall reached 0 bps in 2022.
- Johnson & Johnson's Return on Invested Capital stood at 0.0% in 2022, then soared by 73 bps to 0.0% in 2023, then tumbled by 47 bps to 0.0% in 2024, then surged by 59 bps to 0.0% in 2025, then slipped by 3 bps to 0.0% in 2026.
- The last three Return on Invested Capital figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 0.00% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 0.00% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 0.00% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 0.00% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 0.00% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 0.00% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 0.00% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 0.00% |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 0.00% |
| Dec 28, 2025 | 0.00% |
| Sep 28, 2025 | 0.00% |
| Jun 29, 2025 | 0.00% |
| Mar 30, 2025 | 0.00% |
| Dec 29, 2024 | 0.00% |
| Sep 29, 2024 | 0.00% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | 0.00% |
| Oct 1, 2023 | 0.00% |
| Jul 2, 2023 | 0.00% |
| Apr 2, 2023 | 0.00% |
| Jan 1, 2023 | 0.00% |
| Oct 2, 2022 | 0.00% |
| Jul 3, 2022 | 0.00% |
| Apr 3, 2022 | 0.00% |
| Oct 3, 2021 | 0.00% |
| Jul 4, 2021 | 0.00% |
| Apr 4, 2021 | 0.00% |